A Postmarketing Obervational Study to Assess the Efficacy and Safety of the Factor VIII/von Willebrand Factor Complex (Human), Alphanate, in Preventing Excessive Bleeding During Surgery in Subjects with Congenital Type 3 von Willebrand Disease

Grants and Contracts Details

StatusFinished
Effective start/end date8/25/08 → 10/31/11

Funding

  • Grifols Biologicals Inc: $5,851.00